ArticleHIV medicine2025
Strategies for strengthening same-day ART initiation, tracing people living with HIV lost to follow-up and viral load monitoring mechanisms in Ethiopia.
Article in HIV medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Factors Associated with Antiretroviral Therapy Adherence Among Adolescents Living with HIV in Eastern Cape Province.International journal of environmental research and public health · 2025Article
- Strategies for strengthening same-day ART initiation, tracing people living with HIV lost to follow-up and viral load monitoring mechanisms in Ethiopia.HIV medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTo meet the intended goal of eradicating the Human Immunodeficiency Virus (HIV) epidemic by 2030, the Joint United Nations Program on HIV/Acquired Immunodeficiency Syndrome (AIDS) has set 95-95-95 targets. Ethiopia has made progress towards these targets, but challenges continue to persist.
objectiveTo evaluate the current same-day antiretroviral therapy (ART) initiation status and to develop strategies for strengthening same-day ART initiation, tracing HIV/AIDS patients lost to follow-up, viral suppression and retention of patients in HIV care.
methodsA three-phased (Phase 1, Phase 2 and Phase 3) exploratory sequential mixed methods design was employed in two healthcare facilities in Ethiopia. Strategies were developed based on qualitative findings from in-depth cell phone interviews with 30 healthcare providers, quantitative results from document analysis of 332 clinical records, integration of Phases 1 and 2, application of a theoretical framework, logical reasoning and review of relevant literature.
resultsPhase 1 findings highlighted key barriers to same-day ART initiation, being patient resistance due to fear, stigma and religious concerns, as well as challenges with enrolment procedures and overburdened healthcare providers. Phase 2 results indicated varying retention rates over different time intervals: 35% at 6 months (n = 49), 81% at 12 months (n = 50), 89% from 13 to 18 months (n = 63) and 94% at 24 months (n = 34), with an overall retention in HIV/Care at 59%. Additionally, viral suppression rates were observed to be 93% at 6 months, 95% at 12 months and 86% at 24 months. In Phase 3, 15 strategies were adopted after validation by healthcare experts from HIV programmes at the Federal Ministry of Health and regional health bureaus by using the modified Delphi technique.
conclusionThis study contributed to the understanding of same-day ART initiation in Ethiopia by identifying key challenges that are patient reluctance, socio-economic factors and adherence issues and providing actionable strategies and recommendations for improving same-day ART initiation through targeted interventions and patient-centred strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.